Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Weak wind speeds and power prices weigh on Greencoat UK Wind

(Sharecast News) - Renewable infrastructure fund Greencoat UK Wind said on Wednesday that net cash generation had fallen in the six months ended 31 June amid weaker wind speeds and power prices in H1. Greencoat UK Wind said it had generated net cash of £163.3m during the first six months of 2025, down roughly 41% year-on-year, largely due to lower wind speeds and softer power prices.

Net asset values slipped to £3.18bn, or 143.4p per share, down from 151.2p at year-end, as forecasts for output and power prices were revised lower.

Elsewhere, the group confirmed £131m of share buybacks during the half, repurchasing 101m shares at an average of 130.00p and also announced wind farm disposals worth £181m, bringing total divestments to £222m, all completed at NAV.

Operationally, output came in at 2,581GWh, 14% below budget due to industry-wide low wind conditions.

Greencoat also noted that gearing stood at 41.5% of gross asset value and said it would pay a Q2 dividend of 2.59p per share.

Chairman Lucinda Riches said: "Despite lower portfolio generation due to low wind, the group delivered robust cash generation of £163m to achieve dividend cover of 1.4x.

"We remain confident in our ability to deliver on our objectives of growing the dividend in line with RPI and capital preservation over the long term and extend our track record of outperforming our peers."

As of 1010 BST, Greencoat UK Wind shares were down 0.74% at 120.10p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.